This review highlights that while newer P2Y12 inhibitors improve clinical outcomes in ACS compared to clopidogrel, they increase bleeding risk, and residual thrombotic events necessitate the development of novel antiplatelet strategies.
No takes yet. Share an insight, caveat, or question.
Novel antiplatelet options expand ACS choices; leaves open optimal selection and combinations in practice.
Grove et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: